Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 16, 2018

Primary Completion Date

December 25, 2021

Study Completion Date

December 25, 2021

Conditions

Solid Tumor, Adult

Interventions

BIOLOGICAL

EOC202

EOC202 will be SC injection.

DRUG

Paclitaxel

Paclitaxol will be IV injection

Trial Locations (1)

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Taizhou EOC Pharma Co., Ltd.

INDUSTRY

NCT03600090 - Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter